ALTERATION OF TREATMENT CHOICES AND THE VISUAL PROGNOSIS FOR DIABETIC MACULAR EDEMA IN THE ERA OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR DRUGS

Anti-VEGF therapy has become the first-line treatment since the approval of anti-VEGF drugs for diabetic macular edema. These findings reflect the evolution of diabetic macular edema treatment and highlight the superiority of anti-VEGF therapy and its increased uptake over time.

Authors

Institutions

Publication Details

Journal
Retina
Published
2024-10-18
DOI
https://doi.org/10.1097/iae.0000000000004301
Citations
2
Primary Topic
Retinal Diseases and Treatments
Type
article
Field-Weighted Citation Impact
1.08

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

ALTERATION OF TREATMENT CHOICES AND THE VISUAL PROGNOSIS FOR DIABETIC MACULAR EDEMA IN THE ERA OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR DRUGS

Noriaki Washio, Masahiko Shimura, Masahiko Sugimoto, Kaori Yamamoto et al.
2 citations
Retina
Retinal Diseases and Treatments
1.08
article

ALTERATION OF TREATMENT CHOICES AND THE VISUAL PROGNOSIS FOR DIABETIC MACULAR EDEMA IN THE ERA OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR DRUGS

Noriaki Washio, Masahiko Shimura, Masahiko Sugimoto, Kaori Yamamoto, Taiichi Hikichi, Takashi Koto, Kunihiko Akiyama, Tomoaki Tatsumi, Hiroshi Enaida, Teruyo Kida, Yoshihiro Takamura, Fumiki Okamoto, Sentaro Kusuhara, Fumi Gomi, Yoko Takatsuna, Tomoko Ueda‐Consolvo, Tsuyoshi Iwase, Hiroyuki Nakashizuka, Jiro Kogo, Kei Shinoda, Takao Hirano, Yoshihito Sakanishi, Kazuhiro Kimura, Mariko Sasaki, Kosuke Nishi, Taiji Nagaoka, Rie Osaka, Taiji Sakamoto, Eiko Tsuiki, Yoshinori Mitamura, Shigeo Yoshida, Shunichiro Ueda, Toshinori Murata, Takamasa Kinoshita, Hiroto Terasaki, Yuki Morizane, T. Ueda, Shinichi Sakamoto, Shigehiko Kitano, Akira Minamoto
article en
2 citations

Abstract

Anti-VEGF therapy has become the first-line treatment since the approval of anti-VEGF drugs for diabetic macular edema. These findings reflect the evolution of diabetic macular edema treatment and highlight the superiority of anti-VEGF therapy and its increased uptake over time.

RetinaVol. 45(2)
Nihon University (JP), Kurume University (JP), Kagoshima University (JP), University of Fukui (JP), Hiroshima University (JP), Fukui University of Technology (JP), Center for Science in the Public Interest (United States) (US), Hyogo Medical University (JP), Shinshu University (JP), University of Tsukuba (JP), Jichi Medical University (JP), Tokyo Medical University (JP), Chiba University (JP), Okayama University (JP), St. Marianna University School of Medicine (JP), Yamaguchi University (JP), Saga University (JP), Mie University (JP), Wakayama Medical University (JP), Kyorin University (JP), Kagawa University (JP), Akita University (JP), Keio University (JP), Tokyo Medical University Hachioji Medical Center (JP), Tokyo Medical Center (JP), Showa General Hospital (JP), University of Fukui Hospital (JP), Ohtsuka Eye Hospital (JP), Tokyo Medical University Ibaraki Medical Center (JP), Tokyo Women's Medical University (JP), Juntendo University Urayasu Hospital (JP), Minamiaoyama Eye Clinic (JP), Tachikawa Hospital (JP), Sapporo City General Hospital (JP), Chiba Rosai Hospital (JP), Nihon University Itabashi Hospital (JP), University of Toyama (JP), Nagasaki University (JP), Nara Medical University (JP), Kobe University (JP), Hyogo University (JP), Saitama Medical University (JP), Osaka University of Pharmaceutical Sciences (JP), Tokushima University (JP)
Japan Society for the Promotion of Science
Good health and well-being
Openalex Percentile: Top 22%
Retinal Diseases and Treatments
1.08
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.